Summit Therapeutics PLC SMMT
15.61
(0.77)
(4.70%)
as of 25 Sep
- Market cap
- $13.1B
- P/E
- 0.0×
Follow SMMT
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (192.50%) | (270.95%) | (206.10%) | (292.49%) |
+8 more TTM periods Free account |
|
| (159.09%) | (233.81%) | (181.94%) | (241.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(138.35%) | (225.44%) | (166.51%) | (505.42%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.59) | (0.50) | (0.43) | (0.36) | |
Free Cash Flow |
(459.82) | (384.53) | (323.59) | (270.17) | |
Capital Expenditures |
(1.39) | (0.48) | (0.66) | (0.51) | |
| Other line items | |||||
Cash ROIC |
(34.70%) | (33.54%) | (23.53%) | (62.55%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.54 | 0.32 | 0.30 | 0.29 | |
Depreciation/Fixed assets |
0.10 | 0.10 | 0.14 | 0.16 | |
Capex/Depreciation |
(7.98) | (2.91) | (4.50) | (4.02) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.59) | (0.50) | (0.43) | (0.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates